Abstract
To develop drugs to kill cancer cells, we chemically synthesized a number of anti-cancer agents by adding different side chains to the core backbone of saponin. With the use of bioassay-guided methods, we found one agent that possessed a high cytotoxicity to a number of cancer cell lines. Interestingly, this compound was later found to be an active component of a tradition Chinese herb Paris polyphylla known as Polyphyllin D (PD) (diosgenyl α-L-rhamnopyranosyl- (1→2)-(β-L-ara-binofuranosyl-(1→4)-β-D-glucopyranoside). In China, the rhizome of Paris polyphylla (Chong Lou) has been used as a traditional Chinese medicine to treat a number of cancers including pancreas and liver cancers for a long time. Results from our laboratory demonstrate that PD is a potent anti-cancer agent that bypasses multi-drug resistance (MDR) and induces programmed cell death in R-HepG2 cells over-expressing P-glycoprotein (P-gp). In this paper, we reviewed the mechanisms how PD overcomes the MDR and exhibits a stronger cytotoxicity in the R-HepG2 than its parent line without P-gp through mitochondrial injury.
Keywords: Polyphyllin D, apoptosis, multi-drug resistance, mitochondria, R-HepG2
Current Chemical Biology
Title: Polyphyllin D - A Potential Anti-Cancer Agent to Kill Hepatocarcinoma Cells with Multi-Drug Resistance
Volume: 3 Issue: 1
Author(s): Tim T. Kwok, Siu K. Kong, Ming Li, Ho P. Ho, Bao Yu, Kwok P. Fung, Yick K. Suen, Judy Y.W. Chan, Macey M.S. Lee, Yan C. Li, Rebecca K.Y. Lee, Rose C.Y. Ong and Jenny Y.N. Cheung
Affiliation:
Keywords: Polyphyllin D, apoptosis, multi-drug resistance, mitochondria, R-HepG2
Abstract: To develop drugs to kill cancer cells, we chemically synthesized a number of anti-cancer agents by adding different side chains to the core backbone of saponin. With the use of bioassay-guided methods, we found one agent that possessed a high cytotoxicity to a number of cancer cell lines. Interestingly, this compound was later found to be an active component of a tradition Chinese herb Paris polyphylla known as Polyphyllin D (PD) (diosgenyl α-L-rhamnopyranosyl- (1→2)-(β-L-ara-binofuranosyl-(1→4)-β-D-glucopyranoside). In China, the rhizome of Paris polyphylla (Chong Lou) has been used as a traditional Chinese medicine to treat a number of cancers including pancreas and liver cancers for a long time. Results from our laboratory demonstrate that PD is a potent anti-cancer agent that bypasses multi-drug resistance (MDR) and induces programmed cell death in R-HepG2 cells over-expressing P-glycoprotein (P-gp). In this paper, we reviewed the mechanisms how PD overcomes the MDR and exhibits a stronger cytotoxicity in the R-HepG2 than its parent line without P-gp through mitochondrial injury.
Export Options
About this article
Cite this article as:
Kwok T. Tim, Kong K. Siu, Li Ming, Ho P. Ho, Yu Bao, Fung P. Kwok, Suen K. Yick, Chan Y.W. Judy, Lee M.S. Macey, Li C. Yan, Lee K.Y. Rebecca, Ong C.Y. Rose and Cheung Y.N. Jenny, Polyphyllin D - A Potential Anti-Cancer Agent to Kill Hepatocarcinoma Cells with Multi-Drug Resistance, Current Chemical Biology 2009; 3 (1) . https://dx.doi.org/10.2174/2212796810903010089
DOI https://dx.doi.org/10.2174/2212796810903010089 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Current Pharmaceutical Design Melanoma Immunotherapy: Past, Present, and Future
Current Pharmaceutical Design Sumoylation Pathway as Potential Therapeutic Targets in Cancer
Current Molecular Medicine In Vivo Treatment Efficacy of Essential Oil Isolated from Seeds of <i>Momordica charantia</i> in Streptozotocin-Induced Diabetes Mellitus
Recent Patents on Biotechnology Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Seeking the 5th Base of DNA Using Chromatographic Methods of Analysis
Current Organic Chemistry Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design The Effects of Caffeine on the Cholinergic System
Mini-Reviews in Medicinal Chemistry Perfluoroalkylsulfonyloxyisoflavones: Synthesis and Anti-Proliferation of HL-60
Letters in Organic Chemistry Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets Branched-Chain Amino Acids and Pigment Epithelium-Derived Factor: Novel Therapeutic Agents for Hepatitis C Virus-Associated Insulin Resistance
Current Medicinal Chemistry Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology Nucleoside Phosphorylases
Current Organic Chemistry Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals GSK-3 Inhibitors: Discoveries and Developments
Current Medicinal Chemistry Synthesis, Radiosynthesis and Metabolism of 131I-Y-c(CGRRAGGSC)
Anti-Cancer Agents in Medicinal Chemistry Development of Small-Molecule Inhibitors of Raf
Recent Patents on Anti-Infective Drug Discovery COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry Adeno-Associated Virus-Mediated Gene Transfer in Hematopoietic Stem/Progenitor Cells as a Therapeutic Tool
Current Gene Therapy